WEST HOLLYWOOD, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (Nasdaq: VWAV) today announced it has begun early-stage architecture and feasibility work on a conceptual AI-controlled intelligent radar system concept designed, which if successfully developed, may potentially enhance the survivability and continuity of sensing by distributing radar-related functions across a network of mesh-connected RF units. The system concept is grounded in a resilient, distributed-sensing approach: ra ...

Core Insights - Snail, Inc. will exhibit at the 2026 Game Developers Conference (GDC) in San Francisco from March 9-13, 2026, highlighting its role in the interactive digital entertainment industry [1][2] - The company's participation at GDC 2026 underscores its commitment to strengthening relationships within the global development community and advancing long-term strategic growth initiatives [2][3] Company Initiatives - Snail Games plans to unveil new projects and provide updates on its gaming portfolio, including developments within the ARK franchise during the conference [2] - Leadership and development teams will be available for meetings with partners, investors, and media to discuss ongoing initiatives and expansion strategies [3] Engagement Opportunities - Attendees are invited to visit Snail Games at Booth 1238 on the Expo Floor for discussions on strategic partnerships and sustainable growth within the interactive entertainment ecosystem [3] - Media representatives can schedule interviews, and creators interested in collaboration can reach out via provided contact information [4]

New York, NY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ruanyun Edai Technology Inc. (Nasdaq: RYET, the “Company”) today announced that its Board of Directors has approved a rebranding initiative to rename the Company to Formind Group Inc. (the “Rebranding”). The Company intends to seek shareholder approval for the proposed name change at an upcoming general meeting (the “General Meeting”). Subject to shareholder approval and customary corporate, Nasdaq and administrative processes, the Company intends to change it ...

Mortgage industry veteran to advise on funding strategy, product positioning, and operational scalePROVIDENCE, R.I., Feb. 19, 2026 (GLOBE NEWSWIRE) -- via IBN – Beeline Holdings, Inc. (Nasdaq: BLNE), a technology-enabled, digital mortgage platform, today announced the appointment of mortgage industry veteran Barry Levenson as Executive Strategic Advisor. Mr. Levenson brings more than three decades of experience across mortgage banking, funding strategy, product development, marketing and capital market exec ...

Strategic Transaction Advances Company’s GrowthSARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The ...

Core Viewpoint - Global Crossing Airlines Group, Inc. (GlobalX) will host a conference call on March 5, 2026, to discuss its financial results for Q4 and the full year ended December 31, 2025 [1][2]. Group 1: Conference Call Details - The conference call is scheduled for March 5, 2026, at 8:30 a.m. Eastern time [1][2]. - Interested parties can submit questions via email prior to the call [2]. - The call will be accessible through a toll-free number and an international dial-in number [2]. Group 2: Company Overview - GlobalX operates as a US domestic flag and supplemental airline, utilizing the Airbus A320 family of aircraft [4]. - The company provides domestic and international ACMI and charter flights for passengers and cargo across the US, Caribbean, Europe, and Latin America [4]. - GlobalX is IOSA certified by IATA and holds TCOs for Europe, the UK, and Australia [4].

HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES’s mission is to innovate, educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend se ...

Ultra-High-Speed Blockchain Infrastructure Combined with AI-Driven Decentralized Spaces to Transform Global Finance, Enterprise Economics, and Creator Monetization Enjoys Unsurpassed Efficacy - Significantly – the Transactional Speed Eclipses the Speed at which Currency Values Fluctuate, Enhancing the Prospects of Transaction Closure and Facilitating an International Currency NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- JP3E Holdings, Inc. (OTC: JPTE), today announced the launch of its transformative TBURN × ...

net2phone’s Powerful Hospitality Solution Integrates with Most Popular Property Management SystemsNEWARK, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- net2phone, a global leader in cloud communications and customer-engagement solutions, today introduced an enhanced communications solution for the hospitality industry. net2phone’s cloud-native voice, video, and messaging capabilities synchronize in real time with many popular property management system (PMS) platforms for unified reporting and streamlined workflo ...

Core Viewpoint - Veru Inc. is advancing its clinical programs for innovative treatments targeting cardiometabolic and inflammatory diseases, with a focus on the upcoming presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company's drug development pipeline includes two late-stage novel small molecules: enobosarm and sabizabulin [3] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance weight reduction when combined with GLP-1 RA drugs, aiming for more selective fat loss while preserving lean mass [4] - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when used with semaglutide, led to greater fat loss while preserving lean mass and physical function in older patients [4] - The study involved 168 older patients (≥60 years) and showed that while weight loss was similar across treatment groups, the preservation of lean mass is expected to lead to increased energy expenditure and further weight reduction in longer studies [4] Planned Phase 2b PLATEAU Clinical Study - The upcoming Phase 2b PLATEAU clinical trial will evaluate the effects of enobosarm 3 mg on various health metrics in approximately 200 older patients (age ≥ 65) with obesity [5] - The primary efficacy endpoint is the percent change in total body weight at 68 weeks, with an interim analysis planned at 34 weeks [5] - The study aims to assess the ability of enobosarm to overcome weight loss plateaus in patients receiving GLP-1 RA treatment, with a focus on preserving muscle mass and physical function [6]